Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma

BACKGROUND: A major barrier to effective treatment of glioblastoma (GBM) is the large intertumoral heterogeneity at the genetic and cellular level. In early phase clinical trials, patient heterogeneity in response to therapy is commonly observed; however, how tumor heterogeneity is reflected in indi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Skaga, Erlend, Kulesskiy, Evgeny, Fayzullin, Artem, Sandberg, Cecilie J., Potdar, Swapnil, Kyttälä, Aija, Langmoen, Iver A., Laakso, Aki, Gaál-Paavola, Emília, Perola, Markus, Wennerberg, Krister, Vik-Mo, Einar O.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6593575/
https://ncbi.nlm.nih.gov/pubmed/31238897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5861-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados